Evaluation of an irreversible, mutant-selective inhibitor of EGFR mutations
CO-1686 has demonstrated a good tolerability and promising efficacy against T790M epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC).
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.